Pure Bioscience Performance
| PUREDelisted Stock | USD 0.09 0.03 26.83% |
The company holds a Beta of 1.67, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Pure Bioscience will likely underperform. Pure Bioscience right now holds a risk of 0.0%. Please check Pure Bioscience potential upside, as well as the relationship between the kurtosis and day typical price , to decide if Pure Bioscience will be following its historical price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Pure Bioscience has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound basic indicators, Pure Bioscience is not utilizing all of its potentials. The current stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
| Begin Period Cash Flow | 2.5 M | |
| Total Cashflows From Investing Activities | -81 K |
Pure |
Pure Bioscience Relative Risk vs. Return Landscape
If you would invest 8.78 in Pure Bioscience on September 13, 2024 and sell it today you would earn a total of 0.00 from holding Pure Bioscience or generate 0.0% return on investment over 90 days. Pure Bioscience is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than Pure, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Pure Bioscience Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Pure Bioscience's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Pure Bioscience, and traders can use it to determine the average amount a Pure Bioscience's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| PURE |
Based on monthly moving average Pure Bioscience is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Pure Bioscience by adding Pure Bioscience to a well-diversified portfolio.
Pure Bioscience Fundamentals Growth
Pure Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Pure Bioscience, and Pure Bioscience fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Pure Pink Sheet performance.
| Return On Equity | -1.29 | ||||
| Return On Asset | -0.62 | ||||
| Profit Margin | (2.02) % | ||||
| Operating Margin | (1.98) % | ||||
| Current Valuation | 13.51 M | ||||
| Shares Outstanding | 111.36 M | ||||
| Price To Earning | 12.49 X | ||||
| Price To Book | 3.85 X | ||||
| Price To Sales | 8.00 X | ||||
| Revenue | 1.85 M | ||||
| EBITDA | (3.27 M) | ||||
| Cash And Equivalents | 511 K | ||||
| Cash Per Share | 0.01 X | ||||
| Total Debt | 239 K | ||||
| Debt To Equity | 0.09 % | ||||
| Book Value Per Share | 0.03 X | ||||
| Cash Flow From Operations | (2.42 M) | ||||
| Earnings Per Share | (0.04) X | ||||
| Total Asset | 4.48 M | ||||
| Retained Earnings | (103.22 M) | ||||
| Current Asset | 6.14 M | ||||
| Current Liabilities | 2.54 M | ||||
About Pure Bioscience Performance
By analyzing Pure Bioscience's fundamental ratios, stakeholders can gain valuable insights into Pure Bioscience's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Pure Bioscience has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Pure Bioscience has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
PURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. PURE Bioscience, Inc. was incorporated in 1992 and is headquartered in Rancho Cucamonga, California. PURE BIOSCIENCE operates under Household Personal Products classification in the United States and is traded on OTC Exchange. It employs 10 people.Things to note about Pure Bioscience performance evaluation
Checking the ongoing alerts about Pure Bioscience for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Pure Bioscience help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Pure Bioscience is not yet fully synchronised with the market data | |
| Pure Bioscience has some characteristics of a very speculative penny stock | |
| Pure Bioscience has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 1.85 M. Net Loss for the year was (3.49 M) with profit before overhead, payroll, taxes, and interest of 1000 K. | |
| Pure Bioscience currently holds about 511 K in cash with (2.42 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| Roughly 41.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Pure Bioscience's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Pure Bioscience's stock is overvalued or undervalued compared to its peers.
- Examining Pure Bioscience's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Pure Bioscience's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Pure Bioscience's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Pure Bioscience's pink sheet. These opinions can provide insight into Pure Bioscience's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Other Consideration for investing in Pure Pink Sheet
If you are still planning to invest in Pure Bioscience check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Pure Bioscience's history and understand the potential risks before investing.
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |